iNtRON Biotechnology is established for R&D of Advanced Bio-active Agent targeting Infectious Organisms. Infectious Organisms,  such as Antibiotics Resistant Bacterias have caused very serious problems to infect Human and various diseases harmful to ‘Human and Animal Healthcare’. To solve these problems, iNtRON has developed “N-Rephasin”, the Cure & Treatment System, and “iNNOPLEX”, the Identification System. First of all, iNtRON has the related 53 patents registered or pending in Korea and PCT, and on the process of the Pre-Clinical step of the Bio-Drug for Antibiotics Resistant Infectious Organisms. The main customers are the government institute and research center of hospitals. And also, iNtRON is preparing for IPO of KOSDAQ. Sales of the iNNOPLEX launched in 2007 has doubled from last year, and the new developed products, N-Rephasin related sales will be added up from this year.